BC Week In Review | Dec 17, 2012
Clinical News

AZD5847: Phase IIa started

AstraZeneca said the Case Western Reserve University School of Medicine began an open-label, South African Phase IIa trial to compare oral AZD5847 for 14 days vs. standard treatment with once-daily oral Rifafour rifampicin/isoniazid/ethambutol/pyrimethamine in about...
BC Innovations | Apr 8, 2010

Combining against tuberculosis

Although a handful of new therapies are in the pipeline to treat tuberculosis, it is unlikely that any single molecule will suffice to treat the disease because of the rapid emergence of drug-resistant strains. Drawing...
Items per page:
1 - 2 of 2